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Abstract: The expansion of bacterial antibiotic resistance is a growing problem today. When 
medical devices are inserted into the body, it becomes especially difficult for the body to 
clear robustly adherent antibiotic-resistant biofilm infections. In addition, concerns about the 
spread of bacterial genetic tolerance to antibiotics, such as that found in multiple drug-resistant 
Staphylococcus aureus (MRSA), have significantly increased of late. As a growing direction in 
biomaterial design, nanomaterials (materials with at least one dimension less than 100 nm) may 
potentially prevent bacterial functions that lead to infections. As a first step in this direction, vari-
ous nanoparticles have been explored for improving bacteria and biofilm penetration, generating 
reactive oxygen species, and killing bacteria, potentially providing a novel method for fighting 
infections that is nondrug related. This review article will first examine in detail the mechanisms 
and applications of some of these nanoparticles, then follow with some recent material designs 
utilizing nanotechnology that are centered on fighting medical device infections.
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Bacterial biofilms and antibiotic-resistant infection
Medical device infections can be frequent and costly depending on the device location 
and the duration of use. Yet the benefits from these devices outweigh this low prob-
ability detriment and therefore continue to be used clinically. For example, peripheral 
or central intravenous catheters (CVCs) resulting in bloodstream infections (BSI) occur 
in about 4–5 out of every 1000 CVC devices inserted,1,2 with an attributed cost per 
infection estimated at US$34,508–$56,000,3,4 and the annual cost of caring for patients 
with CVC-associated BSIs ranges from $296 million to $2.3 billion.5 However, CVCs 
are necessary for the delivery of fluids and medication or for monitoring patient health 
(such as through the drawing of blood or monitoring of blood pressure).
In addition to transcutaneous extracorporeal devices or other medical devices that 
are constantly exposed to the nonsterile environment outside the body, implanted 
devices are also susceptible to infections, resulting in implant failure. For example, 
prosthetic joint replacements are permanently implanted to alleviate pain, promote 
mobility, and improve the quality of life, but such implantations also suffer from the 
risk of infection, which occurs in about 1%–1.5% of all total hip and knee arthroplasties 
(THAs and TKAs, respectively) in the USA.6 Although the chance of infection is 
rare in these procedures, the problem is significant, as periprosthetic implant infec-
tions, which are also known as septic failures and cost about US$70,000 per episode, 
are the most common cause of revision surgery in all TKAs (25%), the third most International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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common cause in all THAs (15%), and the most common 
reason for removal of all TKAs (79%) and THAs (74%).6–8 
Prosthesis device infections are some of the most striking 
medical device infections due to the widespread use of pros-
thesis devices, but other implanted medical devices, such as 
intrauterine devices, mechanical heart valves, pacemakers, 
tympanostomy tubes, and voice prostheses, can similarly 
suffer from infection, and could benefit from new therapies 
beyond antibiotics.9
When a device must be removed to eradicate an infection, 
it is often because bacteria have produced a sticky biofilm 
matrix, forming a strong adhesion to the device surface. 
Immediately after binding to a surface, bacteria begin to 
secrete and collect proteins, polysaccharides, and DNA to 
formulate a biofilm.10,11 An outline of biofilm   pathogenicity 
demonstrating macroscopic biofilm dissemination, a 
  representative micrograph of bacteria embedded in a biofilm 
matrix, and a schematic of biofilm formation is shown in 
Figure 1. Biofilm bacteria are resistant to antibiotic treat-
ment, therefore infection is recalcitrant without prolonged 
treatment or removal of the device.12 After biofilm formation 
occurs, the simplest way to treat the infection is to remove the 
infected surface, which contains the sticky biofilm matrix. 
Yet, with permanent fixtures, such as prosthetic devices, 
device removal can be difficult or debilitating to the patient, 
especially if they are very young or old. In addition, chronic 
infections that do not respond to antibiotic treatment and 
require removal of adjacent devitalized bone and soft tissue, 
and may also require plastic surgery.13
Bacterial genetic tolerance to antibiotics is another current 
problem in the treatment of medical   device-related   infections. 
In particular, multiple drug-resistant   Staphylococcus aureus 
(MRSA) have caused great concern about the spread of 
antibiotic-resistant bacteria, with implant infections (includ-
ing grafts and implantable medical devices) being the third 
most common cause of potential MRSA infections   leading 
to hospitalization between 1999 and 2005.14 More recent 
in-depth analysis found that 56% of all device-associated 
infections with S. aureus were reported as MRSA between 
2006 and 2007.15 The International Nosocomial Infection 
Control Consortium (INNIC) also reported that of all 
S. aureus   isolated, 84.1% contained MRSA internationally 
(with the most recent data from 2008).16 Of equal con-
cern, MRSA infections are costing the health care   system 
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Figure 1 Biofilm pathogenicity in humans is mediated by dissemination and biofilm matrix formation. (A) Possible routes of biofilm dissemination around the body originating 
from sites such as gum disease, catheter, or implant contamination.12 (B) Scanning electron micrographs (SEM) of biofilm matrix, offering protection of resident bacteria 
from eradication, imaged from a clinical endotracheal tube identified as Streptococcus pneumonia. Scale bar shown is 1 µm. (C) Schematic of biofilm-mediated device-related 
infection, starting with bacterial attachment to a device or adsorbed host proteins, leading to biopolymer mediated cell–cell adhesion, maturation, and eventual detachment 
leading to the spread of infection.66
Note: A is reproduced from Hall-Stoodley et al12 and C is reproduced from Otto66 with permission from the publishers.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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up to an estimated US$9.7 billion excess costs, and the 
 percentage of infections with MRSA are expected to con-
tinue to increase.14,16
In addition to MRSA, concerns are growing about all 
bacterial tolerance to antibiotics more generally. One such 
example is the growing bacterial tolerance to the drug long 
considered the antibiotic of last resort, vancomycin. In fact, 
clinically relevant resistance to glycopeptides vancomycin 
and teicoplanin were reported in vancomycin-resistant 
enterococci (VRE) as early as 1992, through the plasmid-
borne transferable gene VanA.17,18 Glycopeptide tolerance in 
other bacteria, such as S. aureus, through VanA gene transfer 
has also been reported, although is clinically rare.18
In addition to bacteria, fungi are also becoming tolerant 
to antibiotic treatments, either through biofilm formation or 
genetic tolerance. Candida albicans is the most frequent of 
these human pathogens, with various strains isolated from 
the clinical setting exhibiting resistance to antifungals, such 
as triazole,19 or developing antibiotic-resistant biofilms,20 
posing a significant threat to the infected individual through 
increased resistance to antifungal treatments. Other patho-
genic Candida species are also being reported with multidrug 
tolerances, such as Candida krusei.21
The use of nanoparticles is a growing new approach 
against biofilm-mediated, drug-resistant, and device-
centered infections. For anti-infection applications, various 
nanomaterials are being developed, such as nanoparticles 
and nanotubes, for direct use as biomedical devices; such 
nanomaterials can be used alone, incorporated onto   surfaces, 
into composites, or as components in sensors such as zinc 
oxide (ZnO) nanoparticles, gold nanoparticles, carbon 
  nanotubes, and iron oxide nanoparticles, respectively, shown 
in Figure 2A–E. These examples, and others, will be further 
reviewed here to understand their antibacterial activity and 
potential applications.
Bacterial response and systemic 
applications of nanoparticles
Nanoparticles, which consist of metals such as silver and 
metal oxides, may be promising agents for antibacterial 
applications. Additionally, nanoparticles may also have 
some   general mechanism of toxicity toward bacteria 
that   mammalian cells do not have. Nanoparticles bind to 
  bacterial cell walls causing membrane disruption through 
direct interactions or through free radical production.22 
  Mammalian cells are able to phagocytose nanoparticles, 
and can   subsequently degrade these particles by lysozomal 
fusion,23 reducing   toxicity and free radical damage. This may 
allow for the selectivity of the same nanoparticle to promote 
tissue-forming cell functions, while also inhibiting bacterial 
functions that lead to infection.
The antibacterial activity of silver has long been known, but 
by decreasing particle size into the nanometer range, surface 
area is increased, and the antibacterial activity of the material 
is increased.24 The use of colloidal silver for   minimizing infec-
tion has been investigated for over 50 years, but with recent 
advances in chemical, biological, and material characterization 
techniques, silver is being more widely adopted in the medical 
community. By binding with DNA, with enzymes that control 
respiration and other critical cell functions, or with chemical 
functionality or receptors on the cell membrane, nanoparticles 
of silver have been very effective against many otherwise 
intractable infectious organisms (such as MRSA and other 
antibiotic-resistant microorganisms).25
Metal oxide nanoparticles are also under investiga-
tion for their inherent antimicrobial properties, which are 
enhanced, or may only exist, when the materials are in the 
nanometer size and in relation to surface area. For example, 
size-dependent antibacterial properties of magnesium oxide 
nanoparticles have been observed against Escherichia coli 
and S. aureus, where it was shown that for 23, 18, 15, 11, 
and 8 nm particles, the smallest 8 nm particles decreased 
bacteria growth the most.26 Dose-dependent antimicrobial 
properties have also been observed for iron oxide and may 
only exist when it is formulated into nanometer, rather than 
micron,   particles.27 Greater ZnO antibacterial activity has 
been observed as particle size decreases into the nanometer 
level in relation to surface area.28 Using nitrogen gas (N2) 
isotherms and the Brunauer–Emmett–Teller equation in the 
relative pressure range (P/Po) of 0.05–0.30, researchers have 
found a direct correlation between surface area, particle size 
(calculated from surface area), and antibacterial activity 
of ZnO, with activity ranging from ∼5%–90% decreased 
bacteria viability among surface areas of 90.4–3.49 m2/g 
(corresponding to calculated ZnO particle sizes from 12 to 
307 nm).28 Furthermore, the authors found that the 4–7 mM 
ZnO colloidal suspension with the highest surface area 
(90.4 m2/g) inhibited 95% of MRSA, Enterococcus faecalis, 
a high-biofilm-producing strain Staphylococcus epidermidis, 
and various other clinically relevant pathogen growths.28 
Despite such positive results, the ZnO suspension was least 
effective against Salmonella typhimurium, inhibiting only 
50% of growth;28 because this is still a relevant pathogen 
(there was, for example, a peanut butter-related outbreak in 
200929), further studies should focus on the mechanism of 
ZnO nanoparticle resistance in this pathogen.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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These studies and others determined that nanoparticle 
antibacterial activity could be mediated by increasing 
reactive oxygen species (ROS) production,30,31 as a result 
of the use of metal oxide nanoparticles due to metal ion 
release (which is related to surface area) or through their 
interaction with ultraviolet (UV) light (which also depends 
on particle size).31,32 For example, iron ions generate 
oxygen free radicals by converting hydrogen peroxide 
(H2O2) to the more reactive hydroxyl radical via the Fenton 
reaction.32 Hydroxyl radicals generated by these iron ions 
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Figure 2 various nanomaterials are being studied for emergent antimicrobial properties and are being used for the design of the next generation of therapeutics and 
biomaterials. Zinc oxide nanoparticles (shown in A) have a high surface area and a particle size of about 12 nm, demonstrating antibacterial activity (scanning electron 
micrograph; scale bar: 20 µm). Vancomycin-coated gold nanoparticles (shown in B), with an inset at the minimum inhibitory concentration, are able to overcome resistance 
in several strains of vancomycin-resistant bacteria (transmission electron micrograph; scale bar: 20 nm).37 The enhanced antimicrobial properties of single-walled carbon 
nanotubes compared with larger diameter multiwalled carbon nanotubes (as shown in C and D, respectively) could be used as conductive biomaterials, in situ sensors, or 
tissue engineering scaffolds (scale bars: 2 µm and 50 nm, as shown in inset).54 Superparamagnetic iron oxide nanoparticles (shown in E; scale bar: 100 nm) with antimicrobial 
properties are being explored for controlled delivery to infection sites.
Notes: A is reprinted with permission from Raghupathi KR, Koodali RT, Manna AC. Size-dependent bacterial growth inhibition and mechanism of antibacterial activity of zinc 
oxide nanoparticles. Langmuir. 2011;27(7):4020–4028. Copyright 2011 American Chemical Society. B is reprinted with permission from Gu H, Ho PL, Tong e, Wang L, Xu B. 
Presenting vancomycin on nanoparticles to enhance antimicrobial activities. Nano Letters. 2003;3(9):1261–1263. Copyright 2003 American Chemical Society. C and D are 
reprinted with permission from Kang S, Mauter MS, Elimelech M. Microbial cytotoxicity of carbon-based nanomaterials: implications for river water and wastewater effluent. 
Environ Sci Technol. 2009;43(7):2648–2653. Copyright 2009 American Chemical Society.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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can depolymerize   polysaccharides, cause DNA strands to 
break, inactivate enzymes, and initiate lipid   peroxidation.33 
Such events would also be accelerated through the 
increased surface area of nanometer compared with micron 
  particles, especially when such nanoparticles penetrate 
the bacteria.
A very detailed analysis of ZnO nanoparticle ROS 
  generation was carried out recently by Lipovsky et al.34 In 
this study, it was found that, when using electron paramag-
netic resonance coupled with the spin-trapping technique, 
the formation of hydroxyl radicals and singlet oxygen in 
water suspensions of ZnO nanoparticles resulted, but the 
possibility of superoxide anion production was ruled out.34 
Moreover, the level of oxy radicals increased   considerably 
when the suspension was irradiated with visible light at the 
range 400–500 nm, demonstrating the ability of nondestruc-
tive visible light (as opposed to UV light) to stimulate ROS 
production in ZnO.34 One limitation of this study was that the 
possibility of H2O2 production by ZnO was not discounted, 
as has been previously observed in suspensions of ZnO as a 
primary mediator of antibacterial activity.30,35,36
An ideal antibacterial entity for treating infection would 
be delivered with high efficiency to the site of infection and 
selectively target bacteria over other cells; the therapeutic 
effectiveness of the entity should also be able to be ascer-
tained. An appropriate target mechanism would direct the 
antibacterial treatment to the site of infection. Antibacterial 
activity would remove and inhibit those organisms relevant 
to infection and would be useful against all virulent strains. 
Finally, therapeutic feedback would provide information 
about the effectiveness of the treatment, location of infec-
tion, and delivery efficiency. Modular nanopharmaceutical 
systems are being designed to address all of these multifunc-
tional capabilities for the ideal bacterial treatment, with the 
ability to mix and match appropriate functions.
One way to achieve such multifunctionality would be to 
tailor nanoparticles for specific applications through   surface 
conjugation. Surface conjugation is the final chemical modi-
fication of nanoparticles, providing the opportunity to deliver 
drugs to the site of infection to selectively interact with (and 
penetrate) the biofilm and bacteria targeted. Figure 3 highlights 
the various ways that surface-active nanoparticles can interact 
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Figure 3 Transmission electron micrographs of Staphylococcus aureus bacteria interacting with nanoparticles including superparamagnetic iron oxide nanoparticles (A and D), 
cowpea chlorotic mottle virus (CCMV) nanoparticles (B and E), and self-assembled cationic peptide nanoparticles (C and F). Magnetic nanoparticles bind to the bacterial cell surface 
resulting in membrane disruption (A) and nanoparticle penetration (D) potentially used for bacterial separations. CCMv binds to a coating of protein A antibodies on S. aureus 
membranes through biotin–streptavidin interactions (B) without penetration (E; inset: close-up view of the coated surface) for targeting of magnetic resonance imaging contrast 
agents.40 S. aureus before (C) and after (F) membrane disruption by self-assembled cationic peptide nanoparticles, leading to a rough surface and the formation of a minicell.41
Note: Scale bars: A, C–F, 100 nm; B, 200 nm. B and E are reprinted from Chemistry and Biology, 14/4, Suci PA, Berglund DL, Liepold L, et al, High-density targeting of a 
viral multifunctional nanoplatform to a pathogenic, biofilm-forming bacterium, 387–398, 2007, with permission from Elsevier. C and F are reproduced from Liu et al with 
permission from the publisher.41International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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with bacteria (S. aureus is shown here as an example) toward 
penetrating, targeting, and disrupting bacteria. Nanoparticle 
conjugation can also improve drug efficacy by increasing the 
number of active drug loading sites (through conjugation of 
multiple selected agents onto one nanoparticle).
It has been shown that antibiotic resistance can be 
overcome in vancomycin-resistant bacteria using gold 
nanoparticles coated with vancomycin (ie, gold functional-
ized with vancomycin [Au@Van]; shown in Figure 2B).37,38 
Vancomycin is an inhibitor of cell-wall synthesis, normally 
binding to D-alanine repeat units (D-ala-D-ala) on the bacte-
rial cell surface, but in vancomycin-resistant bacteria, such 
as VRE, modifications of terminal cell-surface peptides 
(such as to D-lactate) lower antibiotic activity. In a study by 
Gu et al, Au@Van with activity against VRE was prepared 
through the interaction of synthetic gold nanoparticles 
with bis(vancomycin) cystamide, through gold and sulfur 
interactions lowering the minimum inhibitory concentration 
(MIC) of resistant bacteria to between 2 and 4 µg/mL.37 It 
was hypothesized that antibacterial activity increased as a 
consequence of close contact among vancomycin molecules 
(∼31 per nanoparticle), changing the binding properties in 
a phenomenon called “polyvalent inhibition.”39 In a more 
recent study by Fayaz et al, a novel preparation of Au@Van 
effectively inhibited the growth of vancomycin-resistant 
S. aureus at an MIC of 8 µg/mL.38 In this study, gold nano-
particles were synthesized biologically using the fungus 
Trichoderma viride and vancomycin was bound to the surface 
by ionic interactions, allowing the positively charged amine 
groups of vancomycin to interact with the negatively charged 
gold nanosurface. It was hypothesized that the nanoparticles 
bound nonspecifically to cell-surface peptides involved in 
cell-wall synthesis, but no further evidence of this was pro-
vided. Interestingly, both studies with Au@Van found activity 
against E. coli growth, which is normally not inhibited due 
to the inability of vancomycin to penetrate the gram-negative 
bacteria outer membrane.37,38 Fayaz et al proposed that Au@
Van penetrated the gram-negative bacteria membrane, as 
evidenced by pitting that was visible in the cell membrane 
under transmission electron microscopy.38
Selective targeting of nanoparticles to an infection site 
minimizes uptake by surrounding tissues and decreases expo-
sure of nonpathogenic bacterial flora (altering the balance of 
natural flora that would exacerbate virulent bacterial growth). 
Chemical targeting is highly specific and requires identifi-
cation of an epitope (such as a molecule or protein) in the 
bacterial biofilm for nanoparticle delivery. In particular, Suci 
et al found that S. aureus biofilm targeting could be achieved 
through the use of a viral nanoparticle, cowpea chlorotic 
mottle virus (CCMV), coated with antibodies to protein A 
(which is a S. aureus surface protein and virulence factor).40 
It was found that CCMV bound to the surface of S. aureus in 
biofilms (∼30 µm thick), penetrated 17.6 (standard deviation 
3.3) µm during an 80-minute exposure (Figure 4A).40 The 
cage-like protein structure of CCMV could simultaneously be 
loaded with the magnetic resonance imaging (MRI) contrast 
agent gadolinium (Gd) achieving a concentration of 1.8 × 105 
Gd atoms per cell, as determined by inductively coupled 
plasma atomic emission spectroscopy.40
Targeting drugs across the blood–brain barrier (BBB) to 
fight neural tissue infection is another issue with traditional 
infection drug design that is currently being addressed by nan-
otechnology. When targeting brain infection, such as meningi-
tis, nanoparticles may be able to cross the BBB and kill a broad 
spectrum of microorganisms. For example, one study by Liu 
et al found that self-assembled cationic peptide nanoparticles 
synthesized through the incorporation of a cationic peptide 
(composed of six arginine residues), a TAT peptide sequence 
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Figure 4 Staphylococcus aureus biofilm penetration by cowpea chlorotic mottle virus (CCMV) (A) and superparamagnetic iron oxide nanoparticles (SPION) (B), analyzed by 
confocal fluorescence microscopy and Prussian blue histology stains for iron, respectively. (A) S. aureus biofilm penetrated by a CCMV nanoplatform (green fluorescence in 
micrograph) demonstrating a penetration depth of 17.6 µm during an 80-minute exposure (main panel shows the top view of the biofilm, and the right and bottom panels are 
cross-sectional views showing CCMV penetration depth)40 (scale bar: 30 µm). (B) Bulk penetration of SPION into an S. aureus biofilm cannot be observed without magnetic field 
exposure for 1 hour (magnetic field time zero; t = 0), and is enhanced through application of a magnetic field (magnetic field time 20, 40, or 60 minutes; t = 20, 40, or 60).
Note: A is reprinted from Chemistry and Biology, 14/4, Suci PA, Berglund DL, Liepold L, et al, High-density targeting of a viral multifunctional nanoplatform to a pathogenic, 
biofilm-forming bacterium, 387–398, 2007, with permission from Elsevier.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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(recognized by the BBB for cell-membrane translocation), 
and a cholesterol core were useful for fighting neural tissue 
  infection.41 Broad antimicrobial activity was achieved, 
with higher efficacy in killing bacteria and fungi than 
many currently available   antibiotics.41 Moreover, using an in 
vivo mouse model, it was found that the nanoparticles that 
targeted brain infections by crossing the BBB were equally 
as effective as vancomycin alone.41 This shows that, through 
the application of nanotechnology and self-assembly, new 
antimicrobial therapeutics can be designed to target brain 
infections without relying on drugs that bacteria may eventu-
ally develop resistance to.
Nanomaterials possessing superparamagnetic properties, 
such as iron oxide nanoparticles (Figure 2E), can be directed 
in situ using a magnetic field – potentially to the site of infec-
tion. Iron oxide nanoparticles have been used for numerous 
biomedical applications, such as for the separation of biomol-
ecules from bacteria or delivery of antibiotics and drugs, with 
simultaneous enhancement of MRI contrast.42–44 For in vivo 
applications, regional magnetic targeting has been used to 
increase the local concentration of certain magnetic materials 
in one body compartment (for example, the brain or upper or 
lower body). A study by Chertok et al focused on improving 
drug uptake across the BBB using 100 nm superparamagnetic 
iron oxide nanoparticles (SPION) and a 0.4 T static magnetic 
field, where a fivefold increase in nanoparticle exposure was 
achieved in a brain cancer model as determined by MRI.45 It 
has also been demonstrated that a magnetic field can increase 
the uptake of magnetic nanoparticles into bacterial biofilms 
(Figure 4B). Using mixed methods of targeting and imaging, 
SPION could further improve the treatment of infections. 
One such method consists of detecting the location of SPION 
and using an externally applied magnetic field in response. 
For example, Oh et al used ultrasound to visualize an intra-
venous injection of 20 nm SPION and exciting results were 
obtained demonstrating SPION movement under focused 
magnetic fields.46 The introduction of ultrasound as an imag-
ing modality that can be used to visualize SPION opens up 
the possibility of bedside application of feedback-controlled 
magnetic drug delivery for treating various infections.
Nanotextured surfaces for the 
development of antimicrobial 
biomaterials
Nanotextured surfaces that can reduce microbial adhe-
sion, proliferation, and biofilm growth through emergent 
antimicrobial properties, as have been found in materials 
such as ZnO, titanium dioxide (TiO2), polymers, and carbon 
nanotubes, are being studied. Due to its ability to mimic the 
constituent properties of natural tissues, nanotechnology 
is being   heavily investigated as a promising tool in tissue 
engineering and biomaterials. The incorporation of nano-
technology into   tissue engineering has recently been reviewed 
in more detail.47 Briefly, it is believed that nanofeatured 
medical device   surfaces enhance surface energy, increase 
select protein adsorption, promote protein bioactivity, and 
improve subsequent tissue-forming cell functions,47 while 
many researchers now hypothesize that this same action could 
simultaneously prevent bacterial colonization.48,49 This idea 
has been used in industry, as antimicrobial nanoparticles are 
incorporated into numerous paints and other materials that 
affect our daily lives.
Medical devices are being designed through the incor-
poration of carbon nanotubes (Figures 2C and D) into 
sensors50,51 to serve as feedback loops to detect bacteria and 
release antibiotics only when needed (as has been previously 
shown with carbon nanotube–coated titanium, which was 
used, after sensing an infection, to break down a thin film of 
polypyrrole containing antibiotics52). Moreover, researchers 
also benefit from the potential antimicrobial properties of 
these nanomaterials even when not used as sensors.
For example, the antimicrobial properties of carbon nano-
tubes have been documented, with a dependence on carbon 
nanotube diameter. In a series of studies, it was found that 
multiwalled carbon nanotubes (MWNTs) and single-walled 
carbon nanotubes (SWNTs), created as mat-like surfaces, 
inactivated free bacteria when mixed with cultures or adher-
ent bacteria (Figures 5A and C).53–55 Furthermore, SWNTs 
exhibited a greater inactivation percentage, as demonstrated 
by decreased viability and metabolic activity, under both 
conditions.53,54 To explain this observation, gene expression 
of E. coli during exposure to the nanotubes was studied; it was 
found that stress-related gene products were especially high 
in the presence of SWNTs, leading to the conclusion that the 
diameter of nanotubes determined the amount of stress and 
damage caused to the bacteria (MWNTs have larger diam-
eters than SWNTs; see Figures 5B and D for a comparison 
of E. coli morphology on the two surfaces).53
The design of orthopedic implant materials for reducing 
infection could also benefit from the application of nanotech-
nology. In one study by Gabriel et al, it was found that when 
ZnO and TiO2 nanoparticles were pressed into compacts using 
a cold compaction method, a significant reduction in microbial 
adhesion was achieved compared with compacts composed of 
larger micron-sized particles (conventional sizes) of the same 
respective materials.49 This study found that ZnO nanoparticle 
compacts had the greatest antimicrobial behavior, probably due to 
the release of zinc (an antimicrobial metal ion).49 These findings International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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were compounded by the simultaneous finding that osteoblast 
(bone-forming cell) functions were significantly enhanced on the 
nanoparticle compacts for both materials when compared with 
their conventional counterparts.49
Another study by Puckett et al found that the antimicro-
bial properties of conventional titanium used in orthopedics 
could be enhanced through a simple nanosurface modifica-
tion technique called “electron beam evaporation,” which 
evaporates TiO2 using a high-energy electron beam, and 
allows the material to form on any titanium (Ti) surface; such 
surfaces were termed “nanorough.”48 Other Ti nanosurface 
features were created through a process called anodization, 
an electrochemical etching process, to create nanotubular Ti 
and nanotextured Ti.48 Using bacteria live/dead staining, it was 
found that the nanorough surfaces reduced bacteria adhesion 
more than conventional Ti (live plus dead), while nanotubular 
and nanotextured Ti killed more bacteria (percentage of live 
and dead).48 It was concluded that surface fluorine, increased 
the adhesion of all bacteria on the anodized nanosurfaces and 
increased nanoroughness, resulting in higher surface energy, 
material crystallinity, and increased protein adsorption, 
which   controlled bacterial adhesion on select nanofabricated 
  surfaces.48 Because similarly fabricated nanosurfaces also 
enhanced other cell functions, such as skin-forming cells 
(keratinocytes) and osteoblasts, as found in other studies,56,57 it 
was concluded that Ti surfaces nanomodified by electron beam 
evaporation have a strong potential in the future design of more 
effective orthopedic or transcutaneous implant materials.48
Similarly, self-cleaning surfaces based on   nanomaterials are 
already making a significant impact as antimicrobial paints for 
buildings and hospitals. One of the most   popular self-cleaning 
coatings is based on UV light–activated   photocatalytic TiO2 
thin-films, the antimicrobial properties of which have been 
understood for over a decade.58 Yet, it is only recently, through 
AB
CD
100 nm
20 nm
Figure 5 The diameter of the carbon nanotubes determined by transmission electron microscopy (A and C) predicts antimicrobial behavior as visible in scanning electron 
micrographs (B and D).53 A mat-like surface made of multiwalled carbon nanotubes (A) inactivates a small percentage of Escherichia coli, visible as abnormal and flattened 
bacteria on the surface (B). Single-walled carbon nanotubes (C), having a smaller diameter, inactivate a greater percentage of bacteria, causing significant structural disruption 
and bacterial death (D).
Note: Reprinted with permission from Kang S, Mauter MS, Elimelech M. Microbial cytotoxicity of carbon-based nanomaterials: implications for river water and wastewater 
effluent. Environ Sci Technol. 2009;43(7):2648–2653. Copyright 2009 American Chemical Society.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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the application of   nanotechnology and enhanced   optical proper-
ties, that the production of antimicrobial coatings activated in 
visible light (such as by fluorescent light bulbs) has become 
possible. In a study by Caballero et al, it was found that by 
including TiO2 nanoparticles in a paint formulation, bacteria 
were inactivated in the presence of fluorescent lighting alone.59 
Antimicrobial paints used indoors (such as inside a hospital) 
have also been formulated through the application of silver 
nanoparticles. One such technology uses the natural oxida-
tive drying process of vegetable oil to reduce silver into silver 
nanoparticles creating a nontoxic paint that can be used to coat 
wood, glass, steel, and various polymers, with strong activity 
against both gram-positive (S. aureus) and gram-negative 
(E. coli) bacteria (Figure 6) while releasing silver slowly to 
increase the longevity of the antimicrobial activity.60
Environmental and health 
considerations
Lastly, as this review details, although there has been much 
promise for the use of nanomaterials (whether nanoparticles 
or nanostructured surface features) to fight infection, it would 
be remiss not to mention the possible, yet largely unknown, 
environmental consequences of nanomaterials. In particular, 
recent research has exposed the possible environmental and 
toxicological concerns of nanomaterials. This is especially 
true when considering that nanotechnology was estimated 
in 2008 to be a US$10.5 billion industry in the USA 
(eg, through the use of nanotechnology in sunscreens, paints, 
and antimicrobial agents) that is expected to grow to 1 trillion 
by 2015.61,62 Therefore, concerns about the   accidental release 
of nanomaterials (during manufacturing or use) into the 
environment are growing.
Concerns have also been raised about damage to natu-
rally occurring bacteria in the environment. For example, 
a study by Kang et al examined the potential release of 
carbon-based nanomaterials (CBNs), determining that 
patterns of cytotoxicity occurred with SWNT inactivating 
Pseudomonas aeruginosa, E. coli, and S. epidermidis, but 
not Bacillus subtilis.54 High rates of inactivation were also 
found in wastewater effluent and river water, especially with 
SWNTs, implying that certain CBNs might reduce microbial 
activity and potentially decrease microbial diversity.54 In a 
similar type of study by Bradford et al, it was shown that 
silver nanoparticles in a model of river estuarine sediments 
did not reduce microbial diversity (as determined by genetic 
diversity).63 Yet, separate concerns about the environmental 
release of silver nanoparticles have been raised, such as the 
potential spread of silver resistance in bacteria.64,65 Studies 
like these also help raise our awareness about the use of 
nanomaterials in humans for medical purposes, where micro-
bial diversity (of natural microbial flora, which prevents the 
spread of virulent organisms) and resistance to nanomaterials 
(similar to current problems of antibiotic resistance) are of 
paramount concern.
In the area of prevention and treatment of infection, 
it has been proposed that materials not only be used by 
Nanoparticles (NP)
Addition
In situ synthesis
Ag metal + 
oxidizing agent
TiO2 NP
+ light
Paint
Nano-featured
antimicrobial
surface
Cold
compaction
Electron-beam
evaporation
ZnO NP
TiO2 NP
Figure 6 Processes for the creation of nano-featured antimicrobial surfaces using addition,59 in situ synthesis,60 cold compation,49 or electron-beam evaporation48 incorporating 
nanoparticles. During addition, nanoparticles are simply added to the paint and, in the case of TiO2 nanoparticles, are activated using a light source, such as a fluorescent 
light.59 In situ synthesis uses the properties of the paint to reduce silver (Ag) metal into nanoparticles, for example using a metal-catalyzed free-radical-mediated oxidation 
process during the production of silver nanoparticles in vegetable oil–based paints.60 During cold compaction, nanoparticles are pressurized into a nano-featured surface, as 
previously achieved using a simple uniaxial, single-ended compacting hydraulic press held at 275 MPa for 30 seconds, then held at a final pressure of 550 MPa for 1 minute 
before releasing the pressure completely.49 Electron-beam evaporation concentrates a large amount of heat produced by high-energy electron-beam bombardment on the 
source material to be deposited, in this case pure Ti pellets, whereby heating and vaporization occur.48 The vapor flow then condenses onto the substrate surface located at 
the top of the vacuum chamber to control nano-featured or larger surface-feature creation.48International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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professionals (such as during infection treatment by clinicians 
in hospitals) but also by every person (such as nanoparticles 
in paints for use at home or over the counter nanodrugs). For 
this reason, future work must rely on collaboration among 
engineers, clinicians, and environmental scientists (and 
those from other fields as well) to fully characterize such 
nanomaterials in terms of chemistry, impurities, and toxicity. 
With the establishment of safe usage guidelines, nanomateri-
als can be safely used for the important and growing area 
of antibacterial material design. We should be excited (not 
frightened) about what the future holds for nanotechnology 
in these collaborative anti-infection efforts.
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